Search results

  1. E

    Dr Karl Morten - UK researcher based at Oxford University

    I agree that the test is currently meaningless for ME/CFS, but that doesn't mean that the test is inaccurate or a "fake test". On the contrary I would say having a test can only be more valuable than not having a test as long as the test is accurate. ELISA is generally considered to be highly...
  2. E

    Dr Karl Morten - UK researcher based at Oxford University

    That doesn't mean the tests are "fake" as I tried to clarify in my post. They don't yield inaccurate results, they appear to be accurate for what they are measuring (antibodies against GPCR in blood via ELISA). The tests simply imply that based on current research the ELISA tests are meaningless...
  3. E

    Dr Karl Morten - UK researcher based at Oxford University

    Why should they clamp down on something like Celltrend? Is there any reason to believe that their tests are inaccurate? From what I can tell their tests are accurate, their results currently just don't have any meaning for LC and/or ME/CFS. Furthermore their tests are supposedly valuable for...
  4. E

    Trial Report The effectiveness of COVID-19 vaccines to prevent long COVID symptoms: staggered cohort study of data from the UK, Spain, and Estonia, 2024, Català +

    What about non-mild long-term health outcomes that don't directly correlate with the severity of an acute infection, since the rest has been known for years?
  5. E

    Incidence of persistent SARS-CoV-2 gut infection in patients with a history of COVID-19: Insights from endoscopic examination, 2024, Hany et al

    Seems like an easy enough thing to do. I'm guessing their methodology isn't the most rigorous though, at least there are no controls which many other papers have had and other papers seem a bit more rigorous to me as layman. "The median duration since the last infection was reported as 17...
  6. E

    Incidence of persistent SARS-CoV-2 gut infection in patients with a history of COVID-19: Insights from endoscopic examination, 2024, Hany et al

    Incidence of persistent SARS-CoV-2 gut infection in patients with a history of COVID-19: Insights from endoscopic examination Abstract Background and study aims Gut infection is common during acute COVID-19, and persistent SARS-CoV-2 gut infection has been reported months after the initial...
  7. E

    Dr Ron Davis - Updates on ME/CFS research - September 2019 onwards

    Even after decades of research there no such thing as a blood marker for MS exists (and those things that some believe to play an important role such as sNfL and sGFAP are completely different to his experiments from what I can tell), so what they are detecting in their experiments can a priori...
  8. E

    Dr Karl Morten - UK researcher based at Oxford University

    Thanks for sharing. Whilst I share your doubts, what he says on Twitter sounds like a somewhat reasonable approach. I even have some small doubts about the LC cohort (possible BMI problems discussed here), but it will also be nice to see further results for a cohort that has already been studied...
  9. E

    Dr Ron Davis - Updates on ME/CFS research - September 2019 onwards

    I don't think Davis ever made such a claim. I might be wrong this time, but previously when patients were making the claim that half of ME/CFS patients have MS, the basis for that was that Davis had said that they are finding antibodies to MBP in half of their ME/CFS samples (see also the...
  10. E

    Long COVID manifests with T cell dysregulation, inflammation, and an uncoordinated adaptive immune response to SARS-CoV-2 2023 Yin et al

    Now published as the Letter Long COVID manifests with T cell dysregulation, inflammation and an uncoordinated adaptive immune response to SARS-CoV-2 in Nature Immonology. Haven't seen if there's new data compared to the preprints, but the reviewers wanted quite a few changes so perhaps there's...
  11. E

    Serotonin reduction in post-acute sequelae of viral infection, 2023, Wong, Cherry et al

    I contacted one of the authors regarding their interesting findings with questions I had, many of which were also asked in this forum. As such I thought it might be interesting if I provided some of the answers, to be precise my own interpretation of the answers, that I received. The stool...
  12. E

    Preprint Long COVID Disability Burden in US Adults: YLDs and NIH Funding Relative to Other Conditions, 2024, Bonuck et al

    Can’t say much about the methodology used other than that they used YLD (“years lived with disability”) rather than DALYs which others commonly use. I’m not sure how accurate the official source for NIH funding is https://report.nih.gov/funding/categorical-spending#/. It doesn’t include the NIH...
  13. E

    Preprint Long COVID Disability Burden in US Adults: YLDs and NIH Funding Relative to Other Conditions, 2024, Bonuck et al

    Long COVID Disability Burden in US Adults: YLDs and NIH Funding Relative to Other Conditions Abstract Background- Long COVID (LC) is novel, debilitating and likely chronic. Yet, scant data exist about its disability burden to guide scientific research and public health planning. We estimated...
  14. E

    Dr Karl Morten - UK researcher based at Oxford University

    How does one obtain a Chronic Lyme (I'm assuming that this is equivalent to Post-Treatment Lyme Disease Syndrome) cohort? Isn't the diagnosis typically made on the basis of tests that are highly unreliable? Are there serious researchers in the field that have also established rigorous cohorts...
  15. E

    Increased von Willebrand and Factor VIII plasma levels in gynecologic patients with Post-Acute-COVID-Sequela (PASC)/Long COVID, 2024, Bellone et al

    First study seems to be about 6 weeks after the acute infection, third study also seems to be suffering from cohort problems. The second study might also have some problems w.r.t. to that (older population, majority males, smokers, hospitalisation, etc) but looks interesting and rigorous enough...
  16. E

    Persistent Risk of Developing Autoimmune Diseases Associated With COVID-19, 2024, Shoichiro et al

    Persistent Risk of Developing Autoimmune Diseases Associated With COVID-19 Abstract Objective This study aimed to investigate the risk of developing autoimmune diseases associated with coronavirus disease 2019 (COVID-19) in Japan, including long-term risks and risks specific to different...
  17. E

    Increased von Willebrand and Factor VIII plasma levels in gynecologic patients with Post-Acute-COVID-Sequela (PASC)/Long COVID, 2024, Bellone et al

    I quickly scrolled through some of Pretorius publications searching for “von Willebrand”. Typically this didn’t return anything, but they do report some values here https://cardiab.biomedcentral.com/articles/10.1186/s12933-021-01359-7 (I don’t have the energy to go through the cohorts right now...
  18. E

    Increased von Willebrand and Factor VIII plasma levels in gynecologic patients with Post-Acute-COVID-Sequela (PASC)/Long COVID, 2024, Bellone et al

    I'd be somewhat surprised if this holds up, maybe part of the picture for some in this heterogeneous condition but possibly not more. I think anybody with any knowledge in hematology would have looked at VWF before going down the microclot route or at least looked at it alongside. I'm also...
  19. E

    Expanded T lymphocytes in the cerebrospinal fluid of multiple sclerosis patients are specific for Epstein-Barr-virus-infected B cells, 2024, Gottlieb+

    Expanded T lymphocytes in the cerebrospinal fluid of multiple sclerosis patients are specific for Epstein-Barr-virus-infected B cells Significance On average, 13% of the T lymphocytes in the cerebrospinal fluid of people with the first symptoms of multiple sclerosis are specific for autologous...
Back
Top